Page 9 - Locally Advanced News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Axel hoosMichael streitEric ducournauPierre fabre laboratorieBiomarker researchScorpion therapeutics incPierre fabre foundationProduct serviceLocally advancedMetastatic non small cell lungPrecision oncologyPierre fabre laboratoriesChief executive officerPierre fabreChief medical officerResponse evaluation criteria in solid tumors

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkFrance generalUnited kingdomPierre louis germainBrandon owensLigia vela reidAmerican association for cancer researchGiven the companyUniversity of texas md anderson cancer centerCommunications departmentDrug administrationInvestor relations departmentFrench financial markets authority autoritExchange commissionPancreatic cancer

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research Preliminary data show local endoscopic injection of NBTXR3 followed by radiotherapy.

France generalUnited statesUnited kingdomNew yorkPierre louis germainLigia vela reidBrandon owensExchange commissionUniversity of texas md anderson cancer centerInvestor relations departmentAmerican association for cancer researchCommunications departmentFrench financial markets authority autoritDrug administrationGiven the companyPancreatic cancer

ProfoundBio Announces Upcoming Scientific Presentations at SITC 2023

SEATTLE, Sept. 28, 2023 /PRNewswire/ ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate

United statesSociety for immunotherapy of cancerSan diego convention centerAnnual meetingRinatabart sesutecanLocally advancedMetastatic solidExhibit hallsDirected antibody drug conjugateAdvanced solid tumorsDemonstrated broad antitumor activityPromising safety profileTherapeutic indexBased antibody drug conjugatesNovel linker systemFolate receptor alpha

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United statesNew yorkUnited kingdomFrance generalExchange commissionFrench financial markets authority autoritGiven the companyDrug administrationUniversity of texas md anderson cancer centerAmerican association for cancer researchPancreatic cancerAmerican associationCancer centerCancer researchEndoscopic ultrasound guidedLocally advanced